M2Bio to make debut at the Cannabis Expo Johannesburg 2022

CAPE TOWN, SOUTH AFRICA / EINPRESSWIRE / October 28, 2022 / Institute of Biomedical
Research (OTC PINK: MRES) (“M2Bio Sciences” or the “Company”), a bioceutical company
focused on alternative plant-based cannabinoids and mental health therapeutic research is
pleased to share the following update:

The Cannabis Expo is a global hotspot where dynamic businesses come together to exhibit
their innovative cannabis products. The Cannabis Expo serves as the perfect platform to start
conversations regarding the medicinal, financial and agricultural benefits of cannabis.

The event will be held at The Sandton Convention Centre in Johannesburg, South Africa from
the 18th to the 20th of November. M2Bio Sciences will be showcasing two of its premium
consumer CBD-infused brands Medspresso and Liviana: This is the first of many
selected conferences to be attended by M2Bio Sciences, and we are excited to be a part of this
cutting-edge event, Jeff Robinson, CEO of M2Bio Sciences.

”Great to have new companies in attendance like M2Bio Sciences that are not only displaying
their premium CBD products, but are also leaders in cannabis and psychedelics research,-
Silas Howarth, Director of The Cannabis Expo South Africa.

At M2Bio Sciences, we create premium products that are infused with high quality,
pharmaceutical-grade organic CBD. These are ethically sourced, free from harmful additives
and preservatives, and are also THC-free, and therefore have no intoxicating effect. Our
Liviana Range consists of CBD-infused Extra Virgin Olive Oil and CBD-infused Raw Honey.
Our Medspresso range includes Premium CBD-infused Organic Coffee – the award-winning
Tanzanian Peaberry, and an African Blend (Ethiopian and Kenyan), and CBD-infused Rooibos
Tea from the Cederberg mountains. – Michael Sachar, CEO of Food and Beverage.
Visit M2Bio Sciences at Booth 56 at the Cannabis Expo, hosted at the Sandton Convention
Centre in Johannesburg from 18 to 20 November.

About Institute of Biomedical Research Corp./ DBA M2Bio Sciences

Institute of Biomedical Research Corp, is a nutraceutical biotechnology company focused on
alternative plant-based cannabinoids and psilocybin medical research that develops and
commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx,
Medspresso, and Liviana brands. In addition, our research and clinical trials with psilocybin
are aimed at new therapies that will help patients who suffer from alcohol addiction, mental
illness, and cardiovascular diseases. Our mission is to advance botanical-based medicine to the
forefront by deploying best-practice science and medicine, clinical research, and emerging
technologies. The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ
under the trading symbol “MRES”.

Publicly traded company (OTC Pink:MRES)

Website: www.m2bio.co

E-mail: info@m2bio.co

Find us on social media

Instagram: m2bio.sciences

Facebook: M2Bio Sciences

LinkedIn: M2Bio Sciences, Inc.

Forward-Looking Statements:

Safe Harbour Statement – In addition to historical information, this press release may contain statements
that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the
Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995.
Forward-looking statements contained in this press release include the intent, belief, or expectations of
the Company and members of its management team with respect to the Company’s future business
operations and the assumptions upon which such statements are based. Prospective investors are
cautioned that any such forward-looking statements are not guarantees of future performance, and
involve risks and uncertainties and that actual results may differ materially from those contemplated by
such forward-looking statements. Factors that could cause these differences include, but are not limited
to, failure to complete anticipated sales under negotiations, lack of revenue growth, client
discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse
developments with respect to litigation or increased litigation costs, the operation or performance of the
Company’s business units or the market price of its common stock. Additional factors that could cause
actual results to differ materially from those contemplated within this press release can also be found
on the Company’s website. The Company disclaims any responsibility to update any
forward-looking statements.